慢性丙型肝炎患者外周血IL-28B基因型多态性及其对持续病毒学应答的影响

doi:10.3969/j.issn.1672-5069.2017.05.024

Abstract

Na Li.. IL-28B genotype polymorphism and its impact on sustained viral response in patients with chronic hepatitis C receiving standardized antiviral therapy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 600-601.

References

[1] 霍雪平，谢琴秀，江晓平，等. 486例慢性乙型肝炎患者肝组织病理学变化与肝功能指标的相关性研究.实用肝脏病杂志，2015，18（4）:360-363.
[2] 熊陶，胡爱荣，蒋素文，等. 丙型病毒性肝炎病毒基因型与病毒载量及疾病进展的相关性分析. 疾病监测，2015，30（1）:19-22.
[3] 谢俊强，郭小燕，李新华，等. 白细胞介素-28B基因多态性与丙型肝炎病毒感染自然清除的相关性.中华传染病杂志，2012，30（9）:538-541.
[4] 聂红明，陈建杰，汪蓉，等. 中国汉族人群慢性丙型肝炎病毒基因型分布规律研究. 中华流行病学杂志，2012，33（5）:501-504.
[5] 赵璐，冯悦，夏雪山，等. HCV基因型的差异性流行与进化.遗传，2012，34（6）:666-672.
[6] Parda N，Stpień M，Zakrzewska K，et al. What affects response rates in primary healthcare-based programmes An analysis of individual and unit-related factors associated with increased odds of non-response based on HCV screening in the general population in Poland. BMJ Open，2016，6（12）:e013359.
[7] 王剑，杨瑞锋，魏来，等. 丙型肝炎病毒基因型及其宿主基因型的检测及临床意义. 中华检验医学杂志，2012，35（2）:97-100.
[8] Oudshoorn D，van der Hoeven B，Limpens RW，et al. Antiviral innate immune response interferes with the formation of replication-associated membrane structures induced by a positive-strand RNA virus. MBJO，2016，7（6）:213-216.
[9] Li X，Xu H，Ding Z，et al. Association between ABO blood group and HCV-related hepatocellular carcinoma risk in China. Medicine （Baltimore），2016，95（49）:e5587.
[10] 慢性丙型肝炎抗病毒治疗专家委员会.慢性丙型肝炎抗病毒治疗专家共识. 中华实验和临床感染病杂志（电子版），2009，3（3）:343-352.
[11]中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2015年更新版. 实用肝脏病杂志，2016，19（4）：ⅠⅩ-ⅩⅩⅤⅠ.
[12] 苗雅娇，赵守松.40例慢性乙型肝炎轻度患者肝组织病理学变化研究. 实用肝脏病杂志，2012，15（1）:7-9.
[13] Liu H，Zhang T，Yan Y. Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis. Medicine （Baltimore），2016，95（49）:e5555.
[14] 杨建军，李朝霞，田淑菊，等. 慢性丙型肝炎患者自身抗体动态变化与HCV-RNA基因型关系研究.国际检验医学杂志，2012，33（24）:2960-2962.
[15] Johnston SL，Hollingsworth R. Immunoglobulin therapy. Clin Med （Lond），2016，16（6）:576-579.
[16] 苏迎盈，刘慧鑫，汪宁，等. 中国丙型肝炎病毒基因型分布. 中华流行病学杂志，2013，34（1）:80-84.
[17] 刘立明，王海滨，陈霖，等. 白介素28B 基因多态性与慢性丙型肝炎患者抗病毒疗效的相关性研究.中华检验医学杂志，2015，21（3）:155-158.
[18] 胡燕梅，孙燕燕，丁荣华，等. 慢性丙型肝炎患者病毒基因型与IL-28B基因型分布. 实用肝脏病杂志，2013，16（6）:513-516.

IL-28B genotype polymorphism and its impact on sustained viral response in patients with chronic hepatitis C receiving standardized antiviral therapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[2]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[3]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[4]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[5]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[6]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[7]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[8]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[9]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[10]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[11]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[12]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.
[13]	Xu Xi, Dang Yinli, Wu Shuo.. Construction and expression of recombinant eukaryotic expression vector of HCV infection related interferon λ4 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 833-836.
[14]	Ji Xiaoqin, Gong Jian.. Clinical features and antiviral treatment of elderly patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 995-998.
[15]	Zhou Sisi, Shen Youxiu, Li Juan, et al.. Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 689-692.